Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaNeurotoxicityPsychosocial Effects of Cancer and Its TreatmentLong-term Effects Secondary to Cancer Therapy in Children
- Registration Number
- NCT00085176
- Lead Sponsor
- Children's Oncology Group
- Brief Summary
RATIONALE: Cancer therapies may affect the ability of a child's brain and central nervous system to function normally. Learning to identify which patients will develop complications may improve the ability of doctors to plan cancer treatment and improve patient quality of life.
PURPOSE: This clinical trial is studying neurobehavioral changes in children who have received steroid therapy or intrathecal therapy for acute lymphoblastic leukemia.
- Detailed Description
OBJECTIVES:
* Compare neurobehavioral functioning, specifically memory, attention, executive function, visual-motor integration, and processing speed, in children previously treated with steroids (prednisone vs dexamethasone) and intrathecal therapy (methotrexate alone vs methotrexate, cytarabine, and hydrocortisone) for childhood acute lymphoblastic leukemia.
* Correlate non-treatment risk factors, such as gender, age at diagnosis, and time since termination of prior therapy, with impaired neurobehavioral function in these patients.
* Correlate neurobehavioral complications with quality-of-life of these patients.
OUTLINE: This is a multicenter, cohort study. Patients are assigned to 1 of 2 cohorts (prior treatment per CCG-1922 \[prednisone vs dexamethasone\] vs prior treatment per CCG-1952 \[intrathecal (IT) methotrexate vs IT methotrexate, cytarabine, and hydrocortisone\]). Patients in each cohort are stratified according to age at diagnosis, gender, and time since prior treatment termination.
* Cohort A (CCG-1922): Patients undergo physical and neurological examination, neurobehavioral evaluation, and quality of life assessment. Neurobehavioral evaluations assess memory, attention, and executive function.
* Cohort B (CCG-1952): Patients undergo evaluation as above. Neurobehavioral evaluations assess visual-motor integration and processing speed.
PROJECTED ACCRUAL: A total of 448 patients (224 per cohort) will be accrued for this study within 4 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 286
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Two-sided comparisons of various mean neurobehavioral scores between the two treatment arms within each study length of study Data analysis for each of the two clinical trials will be conducted separately. The primary objectives will be two-sided comparisons of various mean neurobehavioral scores between the two treatment arms within each study.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (31)
Children's Hospital Center for Cancer and Blood Disorders
๐บ๐ธAurora, Colorado, United States
Indiana University Melvin and Bren Simon Cancer Center
๐บ๐ธIndianapolis, Indiana, United States
Children's Hospitals and Clinics of Minnesota - Minneapolis
๐บ๐ธMinneapolis, Minnesota, United States
Vanderbilt-Ingram Cancer Center
๐บ๐ธNashville, Tennessee, United States
Phoenix Children's Hospital
๐บ๐ธPhoenix, Arizona, United States
NYU Cancer Institute at New York University Medical Center
๐บ๐ธNew York, New York, United States
Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
๐บ๐ธLong Beach, California, United States
Children's Hospital and Research Center Oakland
๐บ๐ธOakland, California, United States
Children's Hospital and Regional Medical Center - Seattle
๐บ๐ธSeattle, Washington, United States
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
๐บ๐ธFarmington, Connecticut, United States
Cincinnati Children's Hospital Medical Center
๐บ๐ธCincinnati, Ohio, United States
Loma Linda University Cancer Institute at Loma Linda University Medical Center
๐บ๐ธLoma Linda, California, United States
C.S. Mott Children's Hospital at University of Michigan Medical Center
๐บ๐ธAnn Arbor, Michigan, United States
Jonsson Comprehensive Cancer Center at UCLA
๐บ๐ธLos Angeles, California, United States
Alfred I. duPont Hospital for Children
๐บ๐ธWilmington, Delaware, United States
Childrens Hospital Los Angeles
๐บ๐ธLos Angeles, California, United States
Yale Cancer Center
๐บ๐ธNew Haven, Connecticut, United States
Butterworth Hospital at Spectrum Health
๐บ๐ธGrand Rapids, Michigan, United States
Oregon Health and Science University Cancer Institute
๐บ๐ธPortland, Oregon, United States
Masonic Cancer Center at University of Minnesota
๐บ๐ธMinneapolis, Minnesota, United States
Nationwide Children's Hospital
๐บ๐ธColumbus, Ohio, United States
Children's Hospital of Pittsburgh
๐บ๐ธPittsburgh, Pennsylvania, United States
Primary Children's Medical Center
๐บ๐ธSalt Lake City, Utah, United States
Lucille P. Markey Cancer Center at University of Kentucky
๐บ๐ธLexington, Kentucky, United States
Children's National Medical Center
๐บ๐ธWashington, District of Columbia, United States
Blank Children's Hospital
๐บ๐ธDes Moines, Iowa, United States
Holden Comprehensive Cancer Center at University of Iowa
๐บ๐ธIowa City, Iowa, United States
Children's Mercy Hospital
๐บ๐ธKansas City, Missouri, United States
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
๐บ๐ธChapel Hill, North Carolina, United States
Children's Hospital of Philadelphia
๐บ๐ธPhiladelphia, Pennsylvania, United States
M. D. Anderson Cancer Center at University of Texas
๐บ๐ธHouston, Texas, United States